Director Louis W. Sullivan Files Intent to Sell Shares After Option Exercise, Following Recent Sales
EBS has more than doubled off its 52-week low of $4.02.
Summary
Director Louis W. Sullivan filed a Form 144 to sell 25,748 shares, valued at $360,142, after exercising options, adding to over $1.3 million in sales in the last three months.
Key Events · Ownership and Investor Activity · EBS
-
Director Files Intent to Sell
Director Louis W. Sullivan filed a Form 144 to sell 25,748 shares of common stock, valued at approximately $360,142, following a stock option exercise.
-
Recent Insider Selling Activity
This proposed sale follows previous sales by Mr. Sullivan of 104,695 shares, generating approximately $1.34 million in gross proceeds over the past three months.
-
Stock Trading Near 52-Week High
The intent to sell comes as Emergent BioSolutions' stock is trading near its 52-week high, potentially indicating a move to lock in gains.
Analysis · EBS · Life Sciences
Director Louis W. Sullivan has filed a Form 144 indicating an intent to sell 25,748 shares of Emergent BioSolutions common stock, valued at approximately $360,142. This proposed sale follows the exercise of stock options. Notably, Mr. Sullivan has already sold 104,695 shares for gross proceeds of approximately $1.34 million in the past three months. The cumulative selling activity by a director, especially with the stock trading near its 52-week high, suggests a pattern of monetizing equity holdings. While the proposed sale itself is modest, the overall trend of insider selling could be interpreted as a lack of conviction in the company's near-term upside by a board member.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1457 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EBS was trading at $13.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $730M. The 52-week trading range was $4.02 to $14.06. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.